Enanta Pharmaceuticals, Inc. (ENTA) Financial Statements
Enanta Pharmaceuticals, Inc. (ENTA) reported trailing twelve-month revenue of $65.3M (up 0.7% year on year) and net income of -$63.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$36.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ENTAEnanta Pharmaceuticals, Inc.Follow ENTA — free
—
Price chart with a free account
- Market cap
- 339.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 16 Nov, in 23 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2013 Sep 13 | FY2014 Sep 14 | FY2015 Sep 15 | FY2016 Sep 16 | FY2017 Sep 17 | FY2018 Sep 18 | FY2019 Sep 19 | FY2020 Sep 20 | FY2021 Sep 21 | FY2022 Sep 22 | FY2023 Sep 23 | FY2024 Sep 24 | FY2025 Sep 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.1 | 47.7 | 160.9 | 88.3 | 102.8 | 206.6 | 205.2 | 122.5 | 97.1 | 86.2 | 79.2 | 67.6 | 65.3 | 65.3 | |
| Research & development | 16.8 | 18.7 | 23.2 | 40.5 | 57.5 | 94.9 | 142.2 | 136.8 | 174.1 | 164.5 | 163.5 | 131.5 | 106.7 | 86.2 | |
| Operating income | 9.0 | 19.0 | 124.1 | 30.8 | 24.6 | 88.3 | 36.7 | -41.6 | -109.6 | -123.8 | -137.2 | -121.7 | -85.3 | -58.7 | |
| Pre-tax income | 9.6 | 19.3 | 125.5 | 32.6 | 26.9 | 93.1 | 45.6 | -35.0 | -107.6 | -122.2 | -131.0 | -117.8 | -83.5 | -63.1 | |
| Income tax | 0.0 | -15.2 | 46.5 | 10.9 | 9.2 | 21.2 | -0.8 | 1.1 | -28.6 | -0.4 | 2.8 | -1.7 | -1.7 | 0.1 | |
| Net income | 9.6 | 34.4 | 79.0 | 21.7 | 17.7 | 72.0 | 46.4 | -36.2 | -79.0 | -121.8 | -133.8 | -116.0 | -81.9 | -63.2 | |
| Diluted EPS ($) | -0.67 | 1.80 | 4.09 | 1.13 | 0.91 | 3.48 | 2.21 | -1.81 | -3.92 | -5.91 | -6.38 | -5.48 | -3.84 | -2.18 | |
| Diluted shares (mn) | 9.8 | 19.2 | 19.3 | 19.2 | 19.4 | 20.6 | 21.0 | 19.9 | 20.2 | 20.6 | 21.0 | 21.2 | 21.3 | — |
USD millions · SEC XBRL
Enanta Pharmaceuticals, Inc. — questions
- What is Enanta Pharmaceuticals, Inc.'s revenue?
- $65.3M over the twelve months to 2026-06-30, up 0.7% year on year, from its 10-Q and 10-K filings.
- What is Enanta Pharmaceuticals, Inc.'s net income?
- -$63.2M over the twelve months to 2026-06-30.
- What is Enanta Pharmaceuticals, Inc.'s free cash flow?
- -$36.9M over the twelve months to 2026-06-30.
- What are Enanta Pharmaceuticals, Inc.'s diluted earnings per share?
- $-2.18 over the twelve months to 2026-06-30.
Every figure on this page comes from Enanta Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.